IN190791B - - Google Patents

Info

Publication number
IN190791B
IN190791B IN2781DE1998A IN190791B IN 190791 B IN190791 B IN 190791B IN 2781DE1998 A IN2781DE1998 A IN 2781DE1998A IN 190791 B IN190791 B IN 190791B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Carl-Axel Bauer
Jan Trofast
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN190791(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of IN190791B publication Critical patent/IN190791B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2781DE1998 1997-09-19 1998-09-16 IN190791B (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703407A SE9703407D0 (sv) 1997-09-19 1997-09-19 New use

Publications (1)

Publication Number Publication Date
IN190791B true IN190791B (en:Method) 2003-08-23

Family

ID=20408325

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2781DE1998 IN190791B (en:Method) 1997-09-19 1998-09-16

Country Status (38)

Country Link
US (2) US7897646B2 (en:Method)
EP (2) EP1014993B1 (en:Method)
JP (1) JP2001517630A (en:Method)
KR (1) KR20010024140A (en:Method)
CN (1) CN1149998C (en:Method)
AR (1) AR013506A1 (en:Method)
AT (2) ATE222106T1 (en:Method)
AU (1) AU757235B2 (en:Method)
BR (1) BR9812325A (en:Method)
CA (1) CA2302700C (en:Method)
CY (1) CY1106156T1 (en:Method)
CZ (1) CZ295250B6 (en:Method)
DE (2) DE69807239T2 (en:Method)
DK (2) DK1014993T3 (en:Method)
EE (1) EE04297B1 (en:Method)
ES (2) ES2266322T3 (en:Method)
HK (1) HK1045812B (en:Method)
HU (1) HUP0003848A2 (en:Method)
ID (1) ID24838A (en:Method)
IL (1) IL134773A (en:Method)
IN (1) IN190791B (en:Method)
IS (1) IS2715B (en:Method)
MX (1) MXPA00002615A (en:Method)
MY (1) MY127812A (en:Method)
NO (1) NO327176B1 (en:Method)
NZ (1) NZ503173A (en:Method)
PL (1) PL190782B1 (en:Method)
PT (2) PT1014993E (en:Method)
RU (1) RU2199322C2 (en:Method)
SA (1) SA98190773B1 (en:Method)
SE (1) SE9703407D0 (en:Method)
SI (2) SI1014993T1 (en:Method)
SK (1) SK285330B6 (en:Method)
TR (1) TR200000726T2 (en:Method)
TW (1) TW546140B (en:Method)
UA (1) UA72446C2 (en:Method)
WO (1) WO1999015182A1 (en:Method)
ZA (1) ZA988516B (en:Method)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
CA2347856C (en) * 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
ES2291452T3 (es) * 2001-02-06 2008-03-01 Innovata Biomed Limited Formulacion bimodal de polvo seco para inhalacion.
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
PL1921919T3 (pl) * 2005-07-14 2012-09-28 Lithera Inc Ulepszona lipolityczna formulacja o podtrzymywanym uwalnianiu do traktowania lokalnej tkanki tłuszczowej
JP2009519970A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経口投与用製薬剤形の製造方法
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
GB2443287B (en) * 2006-10-17 2009-05-27 Lipothera Inc Methods, compositions and formulations for the treatment of thyroid eye disease
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CN107669664B (zh) 2009-05-29 2020-07-10 珍珠治疗公司 经呼吸递送活性剂的组合物及相关方法和系统
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102000090A (zh) * 2009-08-31 2011-04-06 北京利乐生制药科技有限公司 一种以布地奈德与阿福特罗为活性成分的复方制剂
KR101638301B1 (ko) * 2010-01-15 2016-07-08 네오쎄틱스 인코포레이티드 동결건조 케이크 제제
TW201231042A (en) 2010-11-24 2012-08-01 Lithera Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
WO2015065220A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
JP6899824B2 (ja) 2015-12-04 2021-07-07 メキシケム フロー エセ・ア・デ・セ・ヴェ 薬学的組成物
US11756656B2 (en) 2018-06-14 2023-09-12 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
WO2021048171A1 (en) * 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
WO2021076701A1 (en) 2019-10-17 2021-04-22 Trustees Of Boston University Methods and compositions relating to lung function

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2235626B (en) 1989-09-08 1994-02-09 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
ATE213946T1 (de) 1991-12-18 2002-03-15 Formoterol und budesonide enthaltende zusammensetzung
EP1101493A3 (en) 1991-12-18 2004-01-14 AstraZeneca AB New combination of formoterol and budesonide
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9519692D0 (en) 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
WO1997021680A1 (en) * 1995-11-24 1997-06-19 Smithkline Beecham S.P.A. Quinoline derivatives
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
CA2295076A1 (en) 1997-06-27 1999-01-07 Astra Aktiebolag New combination of antiasthma medicaments
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination

Also Published As

Publication number Publication date
PT1014993E (pt) 2002-12-31
IL134773A0 (en) 2001-04-30
CZ295250B6 (cs) 2005-06-15
ATE329599T1 (de) 2006-07-15
US8461211B2 (en) 2013-06-11
US7897646B2 (en) 2011-03-01
EE04297B1 (et) 2004-06-15
EP1210943B1 (en) 2006-06-14
DK1210943T3 (da) 2006-09-18
EP1014993B1 (en) 2002-08-14
JP2001517630A (ja) 2001-10-09
HK1045812B (en) 2006-12-22
DE69834955T2 (de) 2007-01-25
CN1271287A (zh) 2000-10-25
CN1149998C (zh) 2004-05-19
IL134773A (en) 2005-03-20
AU9192898A (en) 1999-04-12
PT1210943E (pt) 2006-09-29
EP1210943A1 (en) 2002-06-05
SK285330B6 (sk) 2006-11-03
TR200000726T2 (tr) 2000-09-21
SA98190773B1 (ar) 2006-10-02
NO20001401D0 (no) 2000-03-17
SI1014993T1 (en) 2003-02-28
ES2182357T3 (es) 2003-03-01
IS5407A (is) 2000-03-15
HK1045812A1 (en) 2002-12-13
DE69807239D1 (de) 2002-09-19
NO327176B1 (no) 2009-05-04
EE200000145A (et) 2001-02-15
ID24838A (id) 2000-08-24
CY1106156T1 (el) 2011-06-08
KR20010024140A (ko) 2001-03-26
DK1014993T3 (da) 2002-11-11
AR013506A1 (es) 2000-12-27
AU757235B2 (en) 2003-02-06
ATE222106T1 (de) 2002-08-15
MXPA00002615A (es) 2002-04-24
ZA988516B (en) 1999-03-19
RU2199322C2 (ru) 2003-02-27
PL190782B1 (pl) 2006-01-31
US20060189587A9 (en) 2006-08-24
TW546140B (en) 2003-08-11
WO1999015182A1 (en) 1999-04-01
HUP0003848A2 (hu) 2001-08-28
SK3892000A3 (en) 2000-12-11
UA72446C2 (uk) 2005-03-15
DE69834955D1 (de) 2006-07-27
NZ503173A (en) 2001-08-31
EP1014993A1 (en) 2000-07-05
CA2302700C (en) 2010-11-23
IS2715B (is) 2011-02-15
CA2302700A1 (en) 1999-04-01
DE69807239T2 (de) 2003-04-10
US20020042404A1 (en) 2002-04-11
MY127812A (en) 2006-12-29
CZ2000950A3 (cs) 2000-06-14
PL339295A1 (en) 2000-12-04
BR9812325A (pt) 2000-09-05
SI1210943T1 (sl) 2006-10-31
NO20001401L (no) 2000-03-17
SE9703407D0 (sv) 1997-09-19
ES2266322T3 (es) 2007-03-01
US20110097282A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
BE2018C032I2 (en:Method)
CH0944937H2 (en:Method)
BE2013C047I2 (en:Method)
BR9700653A (en:Method)
BR9701757A (en:Method)
CN3056276S (en:Method)
CN3055713S (en:Method)
CN3053170S (en:Method)
CN3053500S (en:Method)
CN3053525S (en:Method)
CN3054099S (en:Method)
CN3054162S (en:Method)
CN3054556S (en:Method)
CN3054902S (en:Method)
CN3055123S (en:Method)
CN3055179S (en:Method)
CN3058025S (en:Method)
CN3055471S (en:Method)
CN3056875S (en:Method)
CN3055603S (en:Method)
CN3056826S (en:Method)
CN3056209S (en:Method)
CN3056251S (en:Method)
CN3058088S (en:Method)
BY4238C1 (en:Method)